Results 31 to 40 of about 373,840 (223)
Erdheim Chester disease: a subtle quiddity; the first case reported from Nepal
Radiology Case Reports, 2020 Erdheim-Chester disease (ECD) is a rare entity throughout the world. This is the first case reported in Nepal. ECD is a rare aggressive, non-Langerhan's histocytosis of unknown origin with classical histological features.
Pawan Singh, MBBS +2 more
doaj +1 more source
The Lancet Gastroenterology and Hepatology, 2017 BACKGROUND REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the restoration of functional control of HBV infection by immunotherapy. We assessed the safety and efficacy of REP 2139 and pegylated interferon alfa-2a in
M. Bazinet +13 more
semanticscholar +1 more source
Journal of the Formosan Medical Association, 2021 Background: Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to the 8 to 14 isomers of other on-market pegylated interferon products, allowing every-two-week injection with high tolerability.
Shih-Jer Hsu +15 more
doaj +1 more source
Journal of Clinical and Translational Hepatology, 2018 Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a.
P. Hu +26 more
semanticscholar +1 more source
Thyrotoxicosis With Pegylated Interferon Alfa-2b [PDF]
Archives of Dermatology, 2010 Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with micrometastatic disease.
Lowndes, SA, Asher, R, Middleton, MR
openaire +2 more sources
Onset of Celiac Disease after Treatment of Chronic Hepatitis C with Interferon Based Triple Therapy
Case Reports in Hepatology, 2015 Background. Patients treated with interferon (IFN) based therapies may develop exacerbation of autoimmune disease. We herein present the case of a 53-year-old female patient who developed celiac disease (CD) as a result of triple therapy (interferon ...
Amandeep Singh +2 more
doaj +1 more source
Журнал инфектологии, 2014 Combination therapy with pegylated interferon-α and ribavirin is the modern standard of chronic hepatitis C treatment [1-3] in Russian Federation [4]. This particular regimen provides achieving of sustained virological response (SVR) in 42-28% of patient
E. Z. Burnevich
doaj +1 more source
The Lancet Gastroenterology and HepatologyBACKGROUND Chronic hepatitis B virus (HBV) remains a global concern, with current treatments achieving low rates of HBsAg seroclearance. VIR-2218 (elebsiran), a small interfering RNA agent against HBV transcripts, reduces HBsAg concentrations.
M. Yuen +14 more
semanticscholar +1 more source
Safety and efficacy of nilotinib after 10 years of interferon
Clinical Management Issues, 2015 Here we describe a case of a woman with chronic myeloid leukemia at high risk, according to the Sokal Index. The patient started interferon alfa-2b (IFN) at standard dose obtaining a major molecular response after about four years of treatment.
Filippo Russo
doaj +1 more source
Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. [PDF]
PLoS ONE, 2013 Interferon-based therapy (IBT) has been the standard of care for hepatitis C virus (HCV) infection. However, conflicting results exist regarding the effects of IBT on risk of developing hepatocellular carcinoma (HCC) and cirrhosis-associated ...
Ching-Sheng Hsu +6 more
doaj +1 more source